580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity

TALAPRO-1 enrolled men with progressive mCRPC and tumor DDRm involved either directly or indirectly in homologous recombination repair (HRR) (11-gene panel). These men had received 1–2 taxane-based chemotherapy and progressed on ≥1 novel hormonal therapy. The primary endpoint was objective response rate ([ORR] per RECIST v.1.1; central review). Exploratory ad hoc biomarker analyses assessed non-DDR/HRR mutational landscape and associations with antitumor activity.